Roche to file Tecentriq in triple negative breast cancer
pharmaphorum media limited | July 04, 2018
Roche is hoping its Tecentriq will be the first immunotherapy approved in tough-to-treat breast cancer after it stayed the spread of “triple negative” disease in a phase 3 trial. When combined with Celgene’s chemotherapy Abraxane (nab-paclitaxel) Tecentriq produced a statistically significant improvement in progression-free survival compared with chemotherapy, in PD-L1 positive first-line metastatic triple negative breast cancer (TNBC) patients. An interim analysis showed an encouraging overall survival benefit in the PD-L1 patient population, Roche added.